Zephyrnet Logo

Tag: immediately

Live Chat Support Tips for 2022 and Beyond

Customer demands have shifted towards digital channels, 24/7 services from multiple devices, but they still demand personalized interactions with humans. How do modern live chat support systems leverage digital tools to deliver the best of both worlds to customers?

The post Live Chat Support Tips for 2022 and Beyond appeared first on Inbenta.

Project Business Automation: Evaluated for Solving Supply Chain Disruption

When material is delayed due to a supply chain bottleneck, there is an immediate impact on the project schedule. Delays create a constraint requiring scheduling adjustments. PBA (project business automation) adjusts the schedule and cost adjustments when new or replacement material is sourced. These alterations are immediately reflected, and margins are automatically adjusted as well. […]

When Dental Practice Meets Carbon Neutrality

By Pianpian Wang“Our mission is to serve five key stakeholders, patients, team, suppliers, community and environment”, says Scott Andersen, the co-founder of Artisan Dental.Artisan...

REMINDER: 2022 Nasdaq Board Diversity Disclosure and D&O Questionnaires

REMINDER: 2022 Nasdaq Board Diversity Disclosure and D&O Questionnaires

As issuers prepare for the end of the 2021 calendar year and the beginning of the 2022 proxy season, many will soon begin circulating director and officer questionnaires. Nasdaq-listed issuers should consider including new questions regarding the diversity of their directors now. To assist listed issuers, Nasdaq has provided sample questions for inclusion in director and officer questionnaires.… More

The post REMINDER: 2022 Nasdaq Board Diversity Disclosure and D&O Questionnaires first appeared on IPO, Then What?.

Raising the Bar Has Not Reduced the Patent Acceptance Rate in Australia

Raising the Bar Has Not Reduced the Patent Acceptance Rate in Australia

High JumpData on patent acceptances into 2021 confirms that the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (‘RtB Act’), which came into effect on 15 April 2013, has had a minimal impact on the rate of patent application acceptance in Australia – and to the extent that an effect is present, it does not run in the direction that might be expected!  Here, I define ‘rate of acceptance’ as the proportion of examined applications that go on to be accepted for grant.  Between 2009 and 2013, the rate at which applications subject to the former (i.e. pre-RtB) provisions were accepted rose from 69% to 72%.  In comparison, the acceptance rate of post-RtB applications has stabilised at around 75% in each year between 2017 and 2021.

Some people may have anticipated that, in raising the standard of inventive step and introducing stricter requirements for enablement and support of claims, the RtB reforms would result in fewer applications being accepted.  I was not one of those people, and I expect that neither were most other patent attorneys.  Those of us who work on behalf of patent applicants are well-aware that, firstly, most of those applicants are seeking patent protection in other jurisdictions that have high standards of patentability, and are not wasting time and money on equivalent Australian applications for inventions that do not meet those standards.  And, secondly, encountering a higher bar to acceptance does not necessarily mean abandoning the application altogether; often it may simply mean settling for a more limited scope of protection.

Perhaps more surprisingly, however, raising standards of patentability has not resulted in applicants making more rounds of amendment to their applications in order to achieve acceptance.  In fact, if anything applications examined under the post-RtB provisions have been, on average, subject to fewer amendments in examination than pre-RtB applications.

Interestingly, in the transition between the two legal regimes, the earliest applications to be examined under the provisions of the RtB Act had acceptance rates in excess of 90%, while acceptance rates of the last applications to be examined under the former provisions fell to below 50%.  These effects are most likely attributable to the respective applicants’ strategies in pursuing early examination of post-RtB applications, and in persisting to the bitter end with some pre-RtB applications.

Another interesting observation is that expedited examination has become increasingly popular in the years since the RtB reforms commenced, rising from just under 6% of all cases in 2014/15 to over 8% in 2020/21.  In particular, expedited examination under the Global Patent Prosecution Highway (GPPH) program rose from just 2.7% of cases in 2013/14 to 5.1% in 2019/20.  In fact, GPPH requests were the majority of all expedited examination requests in every post-RtB year except for the first (2013/14).

Finally, the most recent data confirms (once again) that the duration of patent prosecution (i.e. from examination request through to acceptance, in successful cases) has reduced significantly – from a median of over 600 days, to a little more than 400 days – since commencement of the RtB reforms.  This has been due, in almost exactly equal parts, to the tighter time constraints imposed on applicants, and to reductions in Patent Office delays in commencing examination after a request has been filed.

Read more »

What to Consider when Choosing a Camera Sensor for a Medical Device

Part 2: Incident Irradiance, Exposure, Gain, and Frame Rate Camera sensors are common components of medical devices. In this blog I will discuss in detail how incident light irradiance, exposure time, gain, and frame rate factor into the use of camera sensors for medical devices. The key takeaways are: To capture data or images on […]

The post What to Consider when Choosing a Camera Sensor for a Medical Device appeared first on StarFish Medical.

📕 Clear Steps to Implement a PLG Strategy; When to Hire a CRO; The Secret to Persuasive Sales Copy…

Welcome back to The SaaS Playbook, a bi-weekly rundown of the top articles, tactics, and thought leadership in B2B SaaS. Not a subscriber yet? ⚾ There is plenty of talk about the benefits of employing a product led growth (PLG) strategy, but much less on how to actually implement one. Shimon Tolts, CEO of Datree.io shared the

How To Know If Your Laptop Needs Replacement – IoT Worm

Since remote work has become the norm, the need to have a personal computer has never been more important. A computer, whether a desktop...

How To Improve Your Programming Skills As Developers and Non-Developers

Find out the best ways for you to improve your programming skills regardless of whether you’re a developer, designer, or a marketing specialist!

Top 7 benefits of digitizing Real time data | hIOTron®

Industries are utilizing this document digitization process to transform their businesses to be more cost-effective. As per leftronic report 90% of industries are doing...

💳 10 Amazing Digital Wallets for Online Payments in 2023

For the past couple of years, COVID-19 has steadily made the financial sector take 360 degrees by integrating tech to evolve buying and spending....

DABUS Again Denied in the US and the UK, Part II – the Split Decision in the UK

DABUS Again Denied in the US and the UK, Part II – the Split Decision in the UK DABUS US and UK Part II

In the first article in this series I looked at the US approach to the role of the inventor in patent law and practice, and at the recent decision of Judge Leonie M Brinkema in the United States District Court for the Eastern District of Virginia (‘EDVA’) upholding the USPTO’s decision to refuse two patent applications on the basis that the ‘AI’ machine DABUS is not a human being and therefore cannot be an inventor under US law (Stephen Thaler v Andrew Hirshfeld and the US Patent and Trademark Office, Mem. Op. [PDF 998kB]).  In this article, I shall turn my attention to the split decision of the Court of Appeal of England and Wales in Thaler v Comptroller General of Patents Trade Marks And Designs [2021] EWCA Civ 1374, in which parallel efforts to name DABUS as an inventor have also been rejected, with Thaler’s appeal being dismissed despite a weighty dissent by Lord Justice Birss.

The issues in the UK case are somewhat different, and more nuanced, than in the US.  While all three judges on the Court of Appeal agreed that an ‘inventor’ under the UK law must be a human being, the fact that DABUS is a machine was not immediately determinative of the outcome.  An inventor is not required to play any active role in the filing, prosecution, or grant of a patent in the UK, so arguably there remains a question as to whether an application can be permitted to proceed even if a legally valid inventor has not been – or cannot be – named.  In the event, the answer to this question turned on whether or not the applicant (i.e. Dr Thaler) could satisfy statutory requirements to name the inventor, and to indicate how he is entitled to be granted patents on inventions that he did not claim to have devised himself.

Lord Justice Arnold and Lord Justice Birss disagreed on the outcome, with the tie being broken by Lady Justice Elisabeth Laing, agreeing with Arnold LJ that the DABUS applications should be deemed withdrawn. 

Arnold LJ is the preeminent patent law specialist on the Court of Appeal.  He was elevated to the Court of Appeal in 2019, after being appointed to the High Court in 2008, and as Judge in Charge of the Patents Court in April 2013.  In March 2016 he was appointed as an External Member of the Enlarged Board of Appeal of the European Patent Office.  Impressive as this is, however, Birss LJ is no lightweight.  In 2010 he was appointed as a Specialist Circuit Judge sitting in what was then the Patents County Court.  In 2013 he was appointed to the High Court, and in 2019 he filled the place formerly held by Arnold LJ as Judge in Charge of the Patents Court, before being elevated to the Court of Appeal in January 2021.

So this is a case in which the dissenting judgment must be taken seriously, especially with the possibility still open of an appeal to the Supreme Court.  But for now, at least, the balance of the law remains against DABUS in the UK.

Read more »

Latest Intelligence

spot_img
spot_img